PNV - Banter and General Comments, page-12442

But prices in the west should be dramatically higher and be far closer to the competition. Standard of care because it is a better product not because of the price. It doesn’t need to be 60-50% cheaper than the competition, just 10-20 is plenty. Obviously they need huge volume which means huge opex not good for a small company. If they want to continue down the current path they should be looking to leverage existing resources that companies like JNJ or others already have built on these jurisdictions. Growth is still the most important thing and it doesn’t have to be units sold just revenue needs to continue rising. BARDA trial is fully enrolled so that will dry up and need to be covered by higher prices IMO